Progress of study on survivin in diffuse large B-cell lymphoma--review.
- Author:
Hong-Ju DOU
1
;
Jun-Pei HU
Author Information
1. Department of Hematology, Shanghai Ninth People Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai 200011, China.
- Publication Type:Journal Article
- MeSH:
Apoptosis;
Humans;
Lymphoma, Large B-Cell, Diffuse;
metabolism;
pathology;
Microtubule-Associated Proteins;
biosynthesis
- From:
Journal of Experimental Hematology
2008;16(6):1487-1490
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), which is also a significantly heterogeneous disease. Survivin, a unique member of the inhibitor of apoptosis (IAP) family, is overexpressed in various cancers, including some types of lymphoma. It is found that inhibitor of apoptosis protein, survivin, plays an important role in the development and progression of DLBCL. Survivin is able to inhibit the cell apoptosis, and enhances the cell proliferation. Many studies showed that survivin may be considered as an independent unfavorable prognostic index of DLBCL. The poor prognostic cases early are screened in combination of survivin expression with International Prognostic Index (IPI), and improve the outcome of DLBCL. Survivin selectively expressed in tumor tissue, which provide an ideal target for tumor therapy. Modulation of survivin expression or function may provide a novel approach for experimental therapy in patients with DLBCL. In this review, the progress of study on mechanism of survivin protein, the survivin expression in DLBCL, its significance in diagnosis and therapy of DLBCL, and the prospective trend were summarized.
